-
Innovation Ranking
Innovation Ranking – Kyowa Kirin Co Ltd
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension,...
-
Innovation Ranking
Innovation Ranking – Kirin Holdings Co Ltd
Kirin Holdings Co Ltd (Kirin) manufactures and markets alcoholic and non-alcoholic beverages and pharmaceuticals products. Its major products include beer, wine, hopposhu, new genre, sprits, chu-hi, whiskey, seltzer, kombucha, black tea, coffee, tea, fruit juice, dairy products, carbonated beverages, health/sports beverages, ionized natural water, and pharmaceutical drugs. The company markets its products under Kirin Hyoketsu, Honkirin, James Squire, iMUSE, Cognizin, Kirin Gogo-no-Kocha, Kirin Nama-cha, XXXX, Kirin Ichiban, Berri, Baden, San Miguel Pale Pilsen, Spring Valley, Kirin Nodogoshi Nama, Kirin FREE,...
-
Product Insights
NewNet Present Value Model: Kyowa Kirin Co Ltd’s Rocatinlimab
Empower your strategies with our Net Present Value Model: Kyowa Kirin Co Ltd's Rocatinlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewMycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Mycosis Fungoides Clinical Trial Report Overview A total of 328 mycosis fungoides clinical trials were conducted as of April 2024. The mycosis fungoides clinical trial report provides a comprehensive understanding of the mycosis fungoides clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s Evazarsen Sodium
Empower your strategies with our Net Present Value Model: Ionis Pharmaceuticals Inc's Evazarsen Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
Cell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Reasons to buy the ‘Cell and Gene Therapies in CNS Disorders’ report: The report covers the global scope of drug development focusing mainly on the 8MM including the US, 5EU, Japan, and South Korea. The report focuses on the marketed CGT assets addressing CNS disorders as well as the top five CNS disorders with the most CGT pipeline assets. The report throws light on the competitive landscape of leading CGT agents in CNS Disorders including launch date projections, analyst consensus...
-
Product Insights
NewNet Present Value Model: Kyowa Kirin Co Ltd’s Bardoxolone Methyl
Empower your strategies with our Net Present Value Model: Kyowa Kirin Co Ltd's Bardoxolone Methyl report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Kirin Holdings Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kirin Holdings Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
Innovation and Patenting activity of Kyowa Kirin Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kyowa Kirin Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Thematic Analysis
Consumer Goods M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Consumer Goods Sector